# US 2019/0315688 A1 · Intibtors of tryptophan 2,3-dioxygenase

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2019/0315688 A1
- Document ID: US20190315688A1
- Status: Published application
- Kind: A1
- Application number: 16/317,245
- Filed: 2017-07-11
- Published: 2019-10-17
- Earliest claimed: 2016-07-13
- Assignees: Netherlands Translational Research Center B.V.
- Applicants: Netherlands Translational Research Center B.V.
- Inventors: Adrianus Petrus Antonius De Man; Joost Cornelis Marinus Uitdehaag; Jan Gerard Sterrenburg; Joeri Johannes Petrus De Wit; Nicole Wilhelmina Cornelia Seegers; Antonius Maria Van Doornmalen; Rogier Christian Buijsman; Guido Jenny Rudolf Zaman
- Web page: https://patentgrep.com/patent/US20190315688A1

## CPC

- C07D 209/08: with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 25/18: Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A61P 35/00: Antineoplastic agents
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07D 209/18: Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D 209/20: substituted additionally by nitrogen atoms, e.g. tryptophane
- C07D 401/12: linked by a chain containing hetero atoms as chain links
- C07D 403/10: linked by a carbon chain containing aromatic rings
- C07D 403/12: linked by a chain containing hetero atoms as chain links
- C07D 405/12: linked by a chain containing hetero atoms as chain links
- C07D 407/12: linked by a chain containing hetero atoms as chain links
- C07D 413/12: linked by a chain containing hetero atoms as chain links
- C07D 453/02: containing not further condensed quinuclidine ring systems
- C07D 471/04: Ortho-condensed systems
- C07F 5/027: {Organoboranes and organoborohydrides}
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07F: ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM (metal-containing porphyrins C07D487/22)

## Abstract

The invention relates to a compound of Formula I: Formula I, or pharmaceutically acceptable enantiomers, or salts thereof. The present invention also relates to the use of compounds of Formula (I) as selective inhibitors of tryptophan 2,3-dioxygenase. The invention also relates to the use of the compounds of Formula (I) for the treatment or prevention of cancer and central nervous system disease or disorder, either as a single agent or in combination with other therapies.

## Claims

### Claim 1

A compound of Formula I:
or a pharmaceutically acceptable salt thereof wherein,
R1 is selected from the group consisting of hydrogen or fluoro,
R2 is selected from the group consisting of hydrogen or fluoro,
with the proviso that when R1 is fluoro, R2 is hydrogen and when R1 is hydrogen, R2 is fluoro,
R3 is selected from the group consisting of hydrogen, halogen, (1-6C)alkyl or (1-6C)alkoxy,
R4 is selected from the group consisting of hydrogen, halogen, (1-6C)alkyl or (1-6C)alkoxy,
R5 is selected from the group consisting of hydrogen, halogen, (1-6C)alkyl or (1-6C)alkoxy,
R6 is selected from the group consisting of hydrogen, halogen, (1-6C)alkyl or (1-6C)alkoxy,
A is selected from the group consisting of:
R7 is selected from the group consisting of:
a) hydrogen,
b) hydroxy(1-6C)alkyloxy,
c) hydroxy(1-6C)alkyl,
d) di[(1-6C)alkyl]amino(1-6C)alkyl,
e) aminocarbonyl(1-6C)alkyl,
f) amino(1-6C)alkyl,
g) (6-10C)aryl(1-6C)alkyl,
h) (3-7C)cycloalkyl(1-6C)alkyl,
i) (3-7C)cycloalkyl,
j) (2-7C)heterocycloalkyl(1-6C)alkyl,
k) (2-7C)heterocycloalkyl,
l) (1-9C)heteroaryl(1-6C)alkyl,
m) (1-6C)alkyl,
n) (1-6C)alkoxycarbonyl(1-6C)alkyl,
o) (1-6C)alkoxy(1-6C)alkyl,
p) (1-5C)heteroaryl,
q) (1-6C)alkyloxycarbonyl (1-6C)alkyl,
R7 optionally being substituted with one or more groups selected from halogen, hydroxyl, amino, cyano, hydroxy(1-6C)alkyl, di[(1-6C)alkyl]amino(1-6C)alkyl, (6-10C)aryl, (3-7C)cycloalkyl, (2-7C)heterocycloalkyl, (1-6C)alkyl, (1-6C)alkylcarbonyl, (1-6C)alkyloxycarbonyl, aminosulfonyl, (1-6C)alkylsulfonyl, (1-6C)alkylaminothiocarbonyl, (1-6C)alkylaminocarbonyl or (1-6C)alkoxy,
R8 is selected from the group consisting of:
a) hydrogen,
b) (1-6C)alkyl,
or R7 and R8 form, together with the N atom they are attached to, a (1-5C)heteroaryl or (2-7C)heterocycloalkyl, optionally substituted with one or more halogen, amino or hydroxy(1-6C)alkyl,
R9 is selected from the group consisting of:
a) hydrogen,
b) (1-6)alkyl),
R10 is selected from the group consisting of:
a) hydrogen,
b) (1-6C)alkyl,
c) hydroxy(1-6C)alkyl,
d) (6-10C)aryl(1-6C)alkyl,
e) (3-7C)cycloalkyl(1-6C)alkyl,
f) (3-7C)cycloalkyl,
g) (2-7C)heterocycloalkyl(1-6C)alkyl,
h) (2-7C)heterocycloalkyl,
i) (1-6C)alkoxy(1-6C)alkyl,
j) (1-6C)alkylthio(1-6C)alkyl,
k) (1-6C)alkyl sulfonyl (1-6C)alkyl,
l) (1-6C)alkoxycarbonyl(1-6C)alkyl,
m) (1-6C)alkylamino(1-6C)alkyl,
n) (1-5C)heteroaryl(1-6C)alkyl,
o) N(R101R102),
R10 is optionally substituted with one or more groups selected from halogen, hydroxyl, amino, cyano, (1-6C)alkyl or (2-7C)heterocycloalkyl,
R101 is selected from the group consisting of:
a) hydrogen,
b) (1-6C)alkyl,
R102 is selected from the group consisting of:
a) hydrogen,
b) (1-6C)alkyl.

### Claim 2 (depends on 1)

The compound according to claim 1 wherein R1 is fluoro and R2 is hydrogen.

### Claim 3 (depends on 1)

The compound according to claim 1, wherein
R3 is selected from the group consisting of hydrogen, halogen, or (1-6C)alkyl,
R4 is selected from the group consisting of hydrogen, halogen, (1-6C)alkyl or (1-6C)alkoxy,
R5 is selected from the group consisting of hydrogen or halogen,
R6 is selected from the group consisting of hydrogen or halogen.

### Claim 4 (depends on 1)

The compound according to claim 1, wherein R6 is hydrogen.

### Claim 5 (depends on 1)

The compound according to claim 1, wherein R3 is hydrogen, fluoro or methyl.

### Claim 6 (depends on 1)

The compound according to claim 1, wherein R5 is hydrogen or fluoro.

### Claim 7 (depends on 1)

The compound according to claim 1, wherein R4 is hydrogen, fluoro, chloro or methoxy.

### Claim 8 (depends on 1)

The compound according to claim 1, wherein
A is selected from the group consisting of:
R7 is selected from the group consisting of:
a) hydrogen,
b) hydroxy(1-6C)alkyloxy,
c) hydroxy(1-6C)alkyl,
d) di[(1-6C)alkyl]amino(1-6C)alkyl,
e) aminocarbonyl(1-6C)alkyl,
f) amino(1-6C)alkyl,
g) (6-10C)aryl(1-6C)alkyl,
h) (3-7C)cycloalkyl(1-6C)alkyl,
i) (3-7C)cycloalkyl,
j) (2-7C)heterocycloalkyl(1-6C)alkyl,
k) (2-7C)heterocycloalkyl,
l) (1-9C)heteroaryl(1-6C)alkyl,
m) (1-6C)alkyl,
n) (1-6C)alkoxycarbonyl(1-6C)alkyl,
o) (1-6C)alkoxy(1-6C)alkyl,
p) (1-5C)heteroaryl,
q) (1-6C)alkyloxycarbonyl (1-6C)alkyl,
R7 optionally being substituted with one or more groups selected from halogen, hydroxyl, amino, cyano, hydroxy(1-6C)alkyl, di[(1-6C)alkyl]amino(1-6C)alkyl, (6-10C)aryl, (3-7C)cycloalkyl, (2-7C)heterocycloalkyl, (1-6C)alkyl, (1-6C)alkylcarbonyl, (1-6C)alkyloxycarbonyl, aminosulfonyl, (1-6C)alkylsulfonyl, (1-6C)alkylaminothiocarbonyl, (1-6C)alkylaminocarbonyl or (1-6C)alkoxy,
R8 is hydrogen.

### Claim 9 (depends on 1)

The compound according to claim 1, wherein
A is selected from the group consisting of:
R7 is selected from the group consisting of:
a) hydroxy(1-6C)alkyl,
b) di[(1-6C)alkyl]amino(1-6C)alkyl,
c) amino(1-6C)alkyl,
d) (3-7C)cycloalkyl(1-6C)alkyl,
e) (3-7C)cycloalkyl,
f) (2-7C)heterocycloalkyl(1-6C)alkyl,
g) (2-7C)heterocycloalkyl,
h) (1-6C)alkyl,
R7 optionally being substituted with one or more groups selected from halogen, hydroxyl, amino, cyano, hydroxy(1-6C)alkyl, di[(1-6C)alkyl]amino(1-6C)alkyl, (6-10C)aryl, (3-7C)cycloalkyl, (2-7C)heterocycloalkyl, (1-6C)alkyl, (1-6C)alkylcarbonyl, (1-6C)alkyloxycarbonyl, amino sulfonyl, (1-6C)alkyl sulfonyl, (1-6C)alkylaminothiocarbonyl, (1-6C)alkylaminocarbonyl or (1-6C)alkoxy,
R8 is hydrogen.

### Claim 10 (depends on 1)

The compound according to claim 1, wherein
A is selected from the group consisting of:
R7 is selected from the group consisting of:
a) hydroxy(1-6C)alkyl,
b) amino(1-6C)alkyl
c) di[(1-6C)alkyl]amino(1-6C)alkyl,
d) (2-7C)heterocycloalkyl(1-6C)alkyl,
e) (2-7C)heterocycloalkyl,
f) (1-6C)alkyl,
R7 optionally being substituted with one or more groups selected from fluoro, (1-6C)alkyl or di[(1-6C)alkyl]amino(1-6C)alkyl.
R8 is hydrogen.

### Claim 11 (depends on 1)

A method of using the compound or the pharmaceutically acceptable salt thereof according to claim 1, as an inhibitor of tryptophan 2,3-dioxygenase (TDO) comprising a step of administering the compound or the pharmaceutically acceptable salt thereof to a subject.

### Claim 12 (depends on 1)

A pharmaceutical composition comprising a compound of Formula I or a pharmaceutically acceptable salt thereof according to claim 1, and one or more pharmaceutically acceptable excipients.

### Claim 13 (depends on 1)

A method of using the compound or the pharmaceutically acceptable salt thereof according to claim 1 as a medicament in therapy comprising a step of administering a therapeutically effective amount of said compound or the pharmaceutically acceptable salt thereof to a subject.

### Claim 14 (depends on 1)

A method of using the compound or the pharmaceutically acceptable salt thereof according to claim 1, in the treatment of a disease, a disorder or a condition associated with increased TDO activity, comprising a step of administering said compound or the pharmaceutically acceptable salt thereof to a subject having the disease, the disorder or the condition associated with increased TDO activity.

### Claim 15 (depends on 14)

The method according to claim 14, wherein the disease, disorder or condition is selected from the group consisting of cancer and central nervous system diseases and disorders.

### Claim 16 (depends on 12)

The compound or a pharmaceutically acceptable salt thereof or a pharmaceutical composition according to claim 12, further comprising at least one additional therapeutically active agent.

### Claim 17 (depends on 12)

A method of using the pharmaceutical composition according to claim 12 as a medicament in therapy comprising a step of administering a therapeutically effective amount of said pharmaceutical composition to a subject.

### Claim 18 (depends on 12)

A method of using the pharmaceutical composition according to claim 12 in the treatment of a disease, a disorder or a condition associated with increased TDO activity, comprising a step of administering said pharmaceutical composition to a subject having the disease, the disorder or the condition associated with increased TDO activity.

### Claim 19 (depends on 18)

The method according to claim 18, wherein the disease, disorder or condition is selected from the group consisting of cancer and central nervous system diseases and disorders.

### Claim 20 (depends on 15)

The method according to claim 15, wherein the central nervous system diseases and disorders are selected from the group consisting of neuropsychiatric and neurodegenerative diseases.

### Claim 21 (depends on 19)

The method according to claim 19, wherein the central nervous system diseases and disorders are selected from the group consisting of neuropsychiatric and neurodegenerative diseases.
